R7072

R7072 is a fully human, glycoengineered monoclonal antibody (mAb) developed by Roche that targets the insulin-like growth factor 1 receptor (IGF-1R). It is an afucosylated (glycoengineered) version of the parental antibody R1507, designed to exhibit enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. R7072 binds to IGF-1R and blocks the binding of its ligands, IGF-1 and IGF-2, thereby inhibiting downstream PI3K-AKT and RAS-RAF-MAPK signaling pathways that drive tumor cell proliferation and survival. Preclinical studies have evaluated R7072 as a monotherapy and in combination with anti-HER2 therapies (such as trastuzumab or trastuzumab emtansine) to overcome resistance in HER2-positive breast cancer models, as well as in bispecific formats (such as XGFR) targeting both EGFR and IGF-1R.

Other names

anti-IGF-1R monoclonal antibody R7072anti-IGF1R monoclonal antibody R7072anti-IGF 1R monoclonal antibody R7072glycoengineered R1507glycoengineered version of R1507IGF1R mAB (R7072)IGF1R mAb R7072IGF-1R mAb R7072IGF 1R mAb R7072